Membrane‐binding proteins or polypeptides that bear multiple membrane‐binding sites via oligomerization can be selected as potential membrane crosslinkers to tightly bridge viral particles and host cells at a shorter distance than that regulated by the RBD_ACE2 interaction.[51, 52] However, without intensive validation and precise control of the membrane distance, it might be unrealistic and insecure to apply such membrane crosslinkers as therapeutic inhibitors of viral infection. Here, ACE2 is linked to viral infectious disease.